About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Hematology Highlights: A Post ASH Review
Event
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Current Treatment Algorithm & Disease Complications in ET, PV, Myelofibrosis
By
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
FEATURING
Ayalew Tefferi
By
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
FEATURING
Ayalew Tefferi
1,343 views
March 9, 2020
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Hematology Highlights: A Post ASH Review
15:04
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
New Therapies in AML: Is It Safe to Wait for Genomic Info to Start T…
Feat.
E. Wang
13:32
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
AML Treatment Options: Modulating p53 Pathways, Targeting FLT3 Inhib…
Feat.
E. Wang
10:46
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Harnessing the Immune System - Immunotherapy for AML, Targeting Anti…
Feat.
E. Wang
18:28
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Malignancy-Associated Thrombosis: DOACs in Treatment of Cancer-Assoc…
Feat.
B. McMahon
14:19
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Rivaroxaban Inferior to Warfarin in Prevention of Recurrent Thrombos…
Feat.
B. McMahon
10:47
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 Updates in Indolent NHL: EZH2 Inhibition & Lenalidomide…
Feat.
N. Fowler
11:25
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 Updates in Aggressive NHL: Liso-cel in R/R DLBCL, CD19 Loss…
Feat.
N. Fowler
08:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
CAR T-cell for MCL, LOXO-305 Effective in Pretreated B-Cell, Nivo an…
Feat.
N. Fowler
11:56
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 Myeloma Highlights: Genetic Engineering of T-cells, Dara-VM…
Feat.
A. Rosko
09:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Th…
Feat.
A. Rosko
15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Respons…
Feat.
A. Rosko
17:27
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
CLL Therapy in 2020 - Ibrutinib+ Rituximab Provides Superior PFS and…
Feat.
R. Bociek
15:39
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
CLL Highlights from ASH: Chemo Free Therapy Achieves MRD Clearance, …
Feat.
R. Bociek
09:52
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Impact of Next Generation Sequencing on MDS, Scoring System & Cl…
Feat.
H. Carraway
17:41
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Treatment of 62 y/o Man With Low Risk MDS With Anemia: Data on Lenal…
Feat.
H. Carraway
13:11
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Emerging Therapies in MDS: Novel Oral HMT May Become Basis of New Ba…
Feat.
H. Carraway
13:21
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 AML Update: Is It Safe to Wait for Genomic Info to Start Th…
Feat.
E. Wang
12:03
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 AML Update: Ven-based Therapy Can Provide a Path to AlloSCT…
Feat.
E. Wang
08:48
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 ALL Update: Reduced-intensity Chemo Shows Encouraging Resul…
Feat.
E. Wang
13:02
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Current Treatment Algorithm & Disease Complications in ET, PV, M…
Feat.
A. Tefferi
17:47
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 Update in MPN: Triple Negative ET, Ropeginterferon in PV &a…
Feat.
A. Tefferi